ReviewBlood reviews2020
New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Review in Blood reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR survey.Annals of medicine · 2025Article
- Molecular Expression Differences in Specific Blood Mononuclear Cell-Types Identify Patients With AL Amyloidosis.Journal of cellular and molecular medicine · 2025Article
- Depressive symptoms delayed but subsequently led to the diagnosis of transthyretin amyloidosis: a case report.The Journal of international medical research · 2025Article
- Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy.Annals of clinical and translational neurology · 2023Article
- Diagnosis for Chinese patients with light chain amyloidosis: a scoping review.Annals of medicine · 2023Article
- Amyloidosis in the nasopharynx and larynx: a case report.The Journal of international medical research · 2022Article
- The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis.Insights into imaging · 2022Article
- Idiopathic membranous nephropathy with renal amyloidosis: A case report.Frontiers in medicine · 2022Article
- Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.Journal of immunology research · 2022Article
- Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021Article
- Nerve biopsy: Current indications and decision tools.Muscle & nerve · 2021Review
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
- Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.Bone marrow transplantation · 2021Article
- Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis.Leukemia · 2021Article
- A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.Kidney international · 2021Article
- Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.Nature communications · 2021Article
- AL amyloidosis: advances in diagnosis and management.Blood research · 2020Review
- Optimized Ellagic Acid-Ca Pectinate Floating Beads for Gastroprotection against Indomethacin-Induced Gastric Injury in Rats.Biomolecules · 2020Article
- The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.Cancers · 2020Review
- Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.Colombia medica (Cali, Colombia)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Amyloidosis is a group of disorders characterized by a misfolded protein that deposits in organs and compromise their function. Clinician should have a high index of suspicion because in most cases, the clinical picture is non-specific. Typing of amyloid is of utmost importance and should be an integral part of accurately diagnosing a patient. AL amyloidosis is the most common systemic amyloidosis in the western world in which the misfolded proteins are immunoglobulin light chains secreted by clonal plasma cells. New data about prognostication of AL amyloidosis patients are accumulating. The treatment goal is to eradicate the amyloidogenic plasma cell clone, by using high dose melphalan and/or novel agents (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies against CD38). Early diagnosis is important for effectively treating the patient as late diagnosis hampers chances for organ recovery. ATTR amyloidosis is less recognized but is increasingly seen due to better recognition and improved diagnostic tools. New data about treatment options (patisiran, inotersen and tafamidis) have recently been published and are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.